Andy
Retired committee member
To paraphrase, "We've found changes in the brains of people with "FSS", this then proves that "FSS" is valid category! It certainly doesn't mean that there is an actual disease mechanism at work, oh no!" 
The conclusion
Open access, https://www.jstage.jst.go.jp/article/tjem/250/3/250_137/_html/-char/enWhen patients present with persistent bodily complaints that cannot be explained by a symptom-linked organic pathology (medically unexplained symptoms), they are diagnosed with ‘functional’ somatic syndromes (FSS). Despite their prevalence, the management of FSS is notoriously challenging in clinical practice. This may be because FSS are heterogeneous disorders in terms of etiopathogenesis. They include patients with primarily peripheral dysfunction, primarily centrally driven somatic symptoms, and a mix of both. Brain-imaging studies, particularly data-driven pattern recognition methods using machine learning algorithms, could provide brain-based biomarkers for these clinical conditions.
In this review, we provide an overview of our brain imaging data on brain-body interactions in one of the most well-known FSS, irritable bowel syndrome (IBS), and discuss the possible development of a brain-based biomarker for FSS. Anticipation of unpredictable pain, which commonly elicits fear in FSS patients, induced increased activity in brain areas associated with hypervigilance during rectal distention and non-distention conditions in IBS. This was coupled with dysfunctional inhibitory influence of the medial prefrontal cortex (mPFC) and pregenual anterior cingulate cortex (pACC) on stress regulation systems, resulting in the activated autonomic nervous system (ANS) and neuroendocrine system stimulated by corticotropin-releasing hormone (CRH). IBS subjects with higher alexithymia, a risk factor for FSS, showed stronger activity in the insula during rectal distention but reduced subjective sensitivity. Reduced top-down regulation of the ANS and CRH system by mPFC and pACC, discordance between the insula response to stimulation and subjective sensation of pain, and stronger threat responses in hypervigilance-related areas may be a candidate brain-based biomarker.
FSS are common in all areas of medicine, with patients assigned to different types of specialists depending on the symptoms. These include pain at various locations (abdomen, chest, head, back, muscles or joints), diarrhea or constipation, dizziness, palpitations, fatigue, exhaustion, movement disorders, pseudo-seizures, and more (..). The most prevalent FSS include irritable bowel syndrome (IBS), functional dyspepsia, fibromyalgia, chronic fatigue syndrome, and chronic low-back pain, and these share clinical features
The conclusion
Chronic somatic symptoms without clear organic cause proven by medical examination, called FSS, have not been always managed well in clinical practice despite the high prevalence. The reason is that its pathophysiology is conceptualized as a dysfunction in brain-body interaction which does not originate from a single organ. Moreover, symptoms-based criteria can be adapted to patients with a heterogeneous pathological background, which can be peripheral oriented, brain oriented, and most often mixed. Brain imaging studies over the past 20 years have facilitated our understanding of the contribution of the brain to FSS etiopathogenesis. Our brain imaging studies in patients with IBS provided information on the mechanism of FSS: the influence of an unpredictable situation on brain processing of noxious visceral perception, dysfunction of brain regulation of the stress response system including the ANS and CRH related system, and the stronger activity in the visceral perception cortex with discordant subjective sensations associated with alexithymia. Recent advances in analysis of brain imaging data, such as machine learning begun the challenge to make a brain-based biomarker to diagnose or to predict clinical outcome. From our brain imaging data, the mPFC/ACC and insula projection to hypothalamus, amygdala, and PAG associated with the ANS and CRH related system as top-down regulation, and cognitive and emotional modulation or discrepancy between subjective sensation and physiological perception can be a possible candidate brain-based biomarker. There is still a huge gap between what brain imaging studies have provided so far and a real tool for clinical practice. Therefore, it is desirable that a brain-based biomarker will be developed from a variety of large data, to be tested in individual patients and to be optimized so that it can predict a target of clinical therapy for each patient.